NEWS & COMMENTS

PROHOST    FILTER

                                                  VANDA (VNDA). MEDAREX (MEDX)  

These Two Firms are the Stars of Today’s News. Both Have Good News and

the Good News They Have is Expected to

Boost their future values.

MEDAREX (MEDX) announced that the FDA has granted Fast Track designation for ipilimumab (also known as MDX- 010) used in combination with chemotherapy (dacarbazine) in previously untreated (first-line) metastatic melanoma patients. The FDA also has granted Fast Track designation for ipilimumab used as a monotherapy in previously treated (second-line) metastatic melanoma patients.

Prohost Comments: This is what we call good news that adds to previous good news, making it better and more convincing news. We love to hear good news about Ipilimumab because this monoclonal antibody therapeutic is developed to suppress a molecule on T cells, which prevents the immune system from fighting cancers. The important target on the T cells is called CTLA- 4. Approval of Medarex’ drug ipilimumab would open the door for this product to treat a variety of cancers, not only one.

READ MORE: Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy

VANDA (VNDA): The good news for this firm comes from a late Phase clinical trials, where the firm’s compound iloperidone has demonstrated statistically significant improvement in the positive and negative symptoms of schizophrenia compared to placebo. The good results bring Vanda closer to filing a New Drug Application with the FDA, probably, in late 2007. Iloperidone, is a new antipsychotic compound and was tested in two doses in a four-week trial with 604 patients with both symptoms of schizophrenia. Positive symptoms of schizophrenia include hallucinations, delusions, racing thoughts and other psychotic symptoms, while negative symptoms include moodiness, anhedonia (inability to feel pleasure), loss of interest, eating and sleep disturbances, and difficulty concentrating.

Prohost Comments: Without comments, the results of trials speak by themselves. They are positive and are promising for the firm and its shareholders. 

READ MORE: Vanda Pharmaceuticals Confirms Iloperidone Efficacy With Positive Phase III Clinical Trial Results in Schizophrenia

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm